A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (269 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: placebopatientpotentialdiagnosis ofwomen of
  Phrases that lowered it: evaluateand safetythe efficacyefficacy andsafety of
• Blinding: triple (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Responsible party: not given (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 9.2% (lowers risk) · Drug's FDA history
• Sponsor's past termination rate: 12.8% (raises risk) · Sponsor's track record
• Sponsor's past trials: 476 (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Maximum age: 64 (raises risk) · Who can join
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 72.8% (lowers risk) · Drug's FDA history
• Number of arms: 5 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 176 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 3449 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients NCT00822744 · started 2008 · scored riskier than 14% of active trials completed
• Open-Label of SPN-820 in Adults With Major Depressive Disorder NCT06235905 · started 2024 · scored riskier than 16% of active trials completed
• A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder NCT06254612 · started 2024 · scored riskier than 7% of active trials completed
• Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder NCT00863798 · started 2009 · scored riskier than 21% of active trials completed
• Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder NCT00798707 · started 2008 · scored riskier than 10% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.